Following the occurrence of cerebral venous thrombosis in very rare cases after vaccination with COVID-19 Vaccine AstraZeneca, a scientist at Greifswald University Hospital has investigated an immunological process in collaboration with European researchers and in scientific exchange with the Paul-Ehrlich-Institut.
The search for the physiological mechanisms that could explain adverse events after vaccination or after therapy with biomedicines is part of the work of the experts at the Paul-Ehrlich-Institut. In the context of these investigations, an immunological mechanism was investigated by Professor Andreas Greinacher, a researcher at Greifswald University Hospital, following an exchange of expertise. To this end, the Greifswald scientist also analysed blood samples from affected individuals together with European scientists and with the support of the Paul- Ehrlich-Institut.
The identification of the possible cause for the occurrence of the very rare thromboses after vaccination with COVID-19 Vaccine AstraZeneca is a prerequisite for possible future therapy options and has not yet been clarified. The particular form of clotting disorders observed after vaccination with COVID-19 Vaccine AstraZeneca must be treated differently than "common" thromboses. The Paul-Ehrlich-Institut has published information on the symptoms to be observed for vaccinated persons and on diagnostics and therapy for medical doctors on its website.
The Paul-Ehrlich-Institut has not participated in the development of any treatment options.
Updated: 22.03.2021
